The Institut Pasteur's Systems Biology Group is a partner in a new international project on applications of artificial intelligence (AI) for the diagnosis and treatment of ovarian cancer. The project, entitled DECIDER, has been granted five-year funding by the European Union.
The aim of the DECIDER project, funded by the European Union's Horizon 2020 program, is to improve personalized treatment of ovarian cancer. Over a five-year period, the goal is to discover new diagnostic tools and effective drug combinations by using data from patients with high-grade serous ovarian cancer.
DECIDER is an international, multidisciplinary project involving 14 institutions in seven different European countries.
The Institut Pasteur's Systems Biology Group, led by Benno Schwikowski, is taking part in the project, with contributions in two areas in particular.
- A novel AI-based algorithm will be devised to define and identify cancer subtypes and the drugs that best correspond to them, based on patient data.
- A platform housing different open source software tools will be developed with the aim of providing physicians with predictive and diagnostic algorithms.
In methodological terms, the team will focus on "explainable" AI algorithms; in other words, physicians will be able to understand how the algorithms make predictions.
The Institut Pasteur has recognized expertise in this area, as demonstrated in recent research by the Systems Biology Group, which set up a similar platform in 2001 that received nearly 5,000 citations in 2020 [source: Google Scholar].
Read the announcement about the DECIDER project on Eurekalert
This study is part of the Cancer Initiative of the Institut Pasteur's strategic plan for 2019-2023.
